Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al
- PMID: 31744825
- DOI: 10.1136/annrheumdis-2019-216557
Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al
Keywords: TNF-alpha; anti-TNF; disease activity; rheumatoid arthritis; treatment.
Conflict of interest statement
Competing interests: GJW has received a research grant from Pfizer (paid to the institution) and honoraria for lectures from UCB, Pfizer, AbbVie, Biogen and BMS. TR has received honoraria for lectures from Pfizer, AbbVie and Regeneron, and a research grant from Genmab.
Comment in
-
Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.Ann Rheum Dis. 2021 Nov;80(11):e173. doi: 10.1136/annrheumdis-2019-216593. Epub 2019 Dec 9. Ann Rheum Dis. 2021. PMID: 31818809 No abstract available.
Comment on
-
Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.Ann Rheum Dis. 2020 Jan;79(1):94-102. doi: 10.1136/annrheumdis-2019-216169. Epub 2019 Oct 19. Ann Rheum Dis. 2020. PMID: 31630117 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
